Antihypertensive Class Labeling Public Health Impact Assessment Being Considered By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Class labeling for antihypertensives on blood pressure reduction and cardiovascular outcomes to be discussed during an April 26 meeting.